The InterMEL consortium analyzed 656 stage II/III primary melanomas and found that tumors with higher UV-associated tumor mutational burden (UV TMB) had better melanoma-specific survival. Authors reported that when mutations attributable to UV mutagenesis were considered separately from other mutation classes, the UV-related fraction of TMB correlated with improved outcomes. This analysis treated mutation types as biologically distinct rather than collapsing them into a single total-TMB figure.
The cohort-level observation is direct: higher UV TMB aligned with lower melanoma-specific mortality in this dataset. The report did not provide mechanistic proof for this association; it documented a statistical relationship in clinically encountered stage II/III tumors and explicitly linked the finding to earlier work in advanced disease.
The study team observed that non-UV TMB—that is, the component of tumor mutational burden not attributed to UV mutagenesis—showed no association with melanoma-specific mortality in these stage II/III cases. Data indicated that the prognostic signal previously reported for total TMB may derive disproportionately from the UV-induced component rather than from all mutation types equivalently.
Authors emphasized this contrast: one mutation class (UV-associated) tracked with outcome while the remaining mutational burden did not. The source did not report specific effect sizes, hazard ratios, or p-values in the abstract; readers should consult the preprint for full statistical details.
The analytic set comprised 656 tumors from stage II/III melanoma patients assembled by the InterMEL study. Investigators focused explicitly on parsing TMB into UV-related mutations versus non-UV mutations to test whether different mutational etiologies had distinct prognostic associations. The preprint states that all data used in the analysis are available on dbGaP under accession phs003099.v2.p1.
The authors noted institutional approvals and participant consent procedures; the Institutional Review Board of the University of New Mexico Health Sciences Center provided ethical approval for this work. The preprint was posted on medRxiv on November 20, 2026.
Prior reports had linked higher total TMB with outcome in advanced melanoma, but those analyses typically treated TMB as a single summary measure. Investigators in the InterMEL analysis argue that disaggregating mutation types clarifies which component of TMB carries prognostic information. The study team reported that their results are consistent with earlier findings in advanced-stage disease but demonstrate that the UV TMB association extends into stage II/III tumors commonly seen in clinical practice.
This extension matters because stage II/III disease represents a different clinical setting—one where decisions about adjuvant therapy and surveillance depend on more subtle prognostic indicators than in metastatic disease.
Authors proposed several biological explanations that could account for the UV TMB–outcome link, while acknowledging that the preprint does not resolve which mechanism is operative. They suggested that differences in neo-antigenicity and immune recognition between UV-derived and non-UV mutations might drive differential tumor behavior. Other biological properties of UV-mutagenized tumors could also contribute, but those possibilities remain hypothetical in this report.
No experimental immune-profiling data or mechanistic assays were presented in the abstract; the authors framed these interpretations as areas for future investigation rather than demonstrated findings.
The authors declared no competing interests. Ethical oversight and participant consent were affirmed; the Institutional Review Board of the University of New Mexico Health Sciences Center gave approval. Funding sources listed include multiple NIH grants provided in the preprint. The dataset supporting the analysis is available on dbGaP (accession phs003099.v2.p1), which the authors provided for transparency and replication.
The preprint makes clear boundaries around its conclusions. The study did not claim to identify causal mechanisms linking UV TMB to improved survival. It did not provide the mechanistic data (for example, detailed immune profiling, functional neo-antigen validation, or prospective validation) necessary to establish why UV-related mutations predict outcome. The abstract also did not report granular statistical estimates in this summary; readers must consult the full preprint for effect sizes and model covariates.
Remaining questions include whether UV TMB can be translated into a clinically actionable biomarker for stage II/III melanoma, how measurement should be standardized across platforms, and whether the association replicates in independent prospective cohorts. These items, along with the biological basis of the association, are explicitly unresolved in the source.